Chronic inhibition of cyclic GMP phosphodiesterase 5A prevents and reverses cardiac hypertrophy. - Wikidata - awgldk - TriplyDB

Chronic inhibition of cyclic GMP phosphodiesterase 5A prevents and reverses cardiac hypertrophy.

Chronic inhibition of cyclic GMP phosphodiesterase 5A prevents and reverses cardiac hypertrophy.

http://www.wikidata.org/entity/Q45235067

about

KMUP-1 suppresses RANKL-induced osteoclastogenesis and prevents ovariectomy-induced bone loss: roles of MAPKs, Akt, NF-κB and calcium/calcineurin/NFATc1 pathways Sildenafil citrate-restored eNOS and PDE5 regulation in sickle cell mouse penis prevents priapism via control of oxidative/nitrosative stress Phosphodiesterase 9A controls nitric-oxide-independent cGMP and hypertrophic heart disease Monoamine oxidase B prompts mitochondrial and cardiac dysfunction in pressure overloaded hearts Multidrug resistance-associated protein 4 regulates cAMP-dependent signaling pathways and controls human and rat SMC proliferation Measurement of cardiac function using pressure-volume conductance catheter technique in mice and rats Sildenafil and cardiomyocyte-specific cGMP signaling prevent cardiomyopathic changes associated with dystrophin deficiency A novel mitochondrial matrix serine/threonine protein phosphatase regulates the mitochondria permeability transition pore and is essential for cellular survival and development Novel Radioligands for Cyclic Nucleotide Phosphodiesterase Imaging with Positron Emission Tomography: An Update on Developments Since 2012 Strategies and methods to study female-specific cardiovascular health and disease: a guide for clinical scientists Novel Perspectives in Redox Biology and Pathophysiology of Failing Myocytes: Modulation of the Intramyocardial Redox Milieu for Therapeutic Interventions-A Review Article from the Working Group of Cardiac Cell Biology, Italian Society of Cardiology Is enhancing cGMP-PKG signalling a promising therapeutic target for heart failure with preserved ejection fraction?Redox regulation of cGMP-dependent protein kinase Iα in the cardiovascular system Signaling effectors underlying pathologic growth and remodeling of the heart Nitric oxide synthases in heart failure Cardiac endothelium-myocyte interaction: clinical opportunities for new heart failure therapies regardless of ejection fraction Erectile dysfunction in heart failure patients: a critical reappraisal Heart failure with preserved ejection fraction: mechanisms, clinical features, and therapies Therapeutic potential of PDE modulation in treating heart disease Systematic review and meta-analysis of the use of phosphodiesterase type 5 inhibitors for treatment of erectile dysfunction following bilateral nerve-sparing radical prostatectomy The cGMP signaling pathway as a therapeutic target in heart failure with preserved ejection fraction Phosphodiesterases and cardiac cGMP: evolving roles and controversies Inhibition of type 5 phosphodiesterase counteracts β2-adrenergic signalling in beating cardiomyocytes Priming the proteasome by protein kinase G: a novel cardioprotective mechanism of sildenafil Beneficial effects of soluble epoxide hydrolase inhibitors in myocardial infarction model: Insight gained using metabolomic approaches Phosphodiesterase-5 inhibition augments endogenous antitumor immunity by reducing myeloid-derived suppressor cell function A critical role for the protein apoptosis repressor with caspase recruitment domain in hypoxia-induced pulmonary hypertension The emperor's new clothes: PDE5 and the heart The immediate effect of sildenafil on right ventricular function in patients with heart failure measured by cardiac magnetic resonance: a randomized control trial The Effect of Sorafenib, Tadalafil and Macitentan Treatments on Thyroxin-Induced Hemodynamic Changes and Cardiac Abnormalities Copper-induced regression of cardiomyocyte hypertrophy is associated with enhanced vascular endothelial growth factor receptor-1 signalling pathway Pak1 as a novel therapeutic target for antihypertrophic treatment in the heart Regulator of G protein signaling 2 mediates cardiac compensation to pressure overload and antihypertrophic effects of PDE5 inhibition in mice Regulation of Mitochondrial Dynamics by Dynamin-Related Protein-1 in Acute Cardiorenal Syndrome Sildenafil ameliorates left ventricular T-tubule remodeling in a pressure overload-induced murine heart failure model Automated imaging reveals a concentration dependent delay in reversibility of cardiac myocyte hypertrophy PDE5A suppression of acute beta-adrenergic activation requires modulation of myocyte beta-3 signaling coupled to PKG-mediated troponin I phosphorylation.Stress-dependent dilated cardiomyopathy in mice with cardiomyocyte-restricted inactivation of cyclic GMP-dependent protein kinase I Ventricular phosphodiesterase-5 expression is increased in patients with advanced heart failure and contributes to adverse ventricular remodeling after myocardial infarction in mice.Role of phosphodiesterase-5 inhibitors in heart failure: emerging data and concepts.

P2860

Q21090734-35B0CD17-7544-41DA-A7CA-4C8C92017B24 Q21559608-1238B556-337B-43BE-BFB3-47036E2BE5DA Q24323316-8A825528-0B6B-4694-9D79-A2CA3559EBA6 Q24619376-148CFA3B-6C36-4673-A7F8-DD726EACCB99 Q24641873-25738AC8-EE82-42A0-9E12-57FC8C363E57 Q24648818-0FD1026F-C7EE-444B-AEC3-6F389F1B9181 Q24655371-4DB939CB-7B3C-4571-9F53-840AC876B90A Q24674156-A34747DF-1133-48EA-B343-3312FBB419BE Q26746978-5EE65E48-F8C9-42A4-BD8B-D3819F3DDBD0 Q26749044-8DA65077-1DB5-402D-BAE6-958EF499FB6F Q26765793-6F468C20-D481-41BE-A0D7-F4A2D828EAFF Q26765931-573D7360-D592-4D0A-B92B-85EEEC09F87D Q26800060-5C7BA5E2-5DDE-4554-888D-9C74BAD2F38C Q26825154-25D69171-C9F3-493F-B964-40D8A4B29AE9 Q26830146-0107EF92-B3FF-4C29-AAAD-D691C7BB7D62 Q26853363-6A8776CC-225C-4233-8379-F9C03B3CD460 Q26853624-51A7F89F-A49F-4F82-B668-F1ABB893D3A4 Q27000263-07FD16E0-8FBC-4DB8-902B-160A77CD4AFD Q27005761-DD9954AF-496A-48D6-A729-EBC79DA79701 Q27013000-6BCD9BC7-37D2-4091-A113-261F0901BEFE Q27024279-D4D5D4E4-4205-4340-99AB-CE066D7526D0 Q27692588-01249829-BC5A-4622-84D4-E094064D6DD4 Q27967859-55A5C8B4-4E26-4781-9FB0-6A748F4BA3A3 Q28084015-BC7E4ED0-8DE1-46B2-96F0-41453F4A4198 Q28397084-8BD3F240-1111-424F-9012-F5C74D239860 Q28510096-906953DC-4528-4DE2-916A-8D27AC107ADC Q28513703-853A318F-77FA-44BE-9248-4EB71E0BA9EE Q28543897-4DC6CA4C-3434-46F4-84AC-8BC668078A0E Q28544798-8D74CC93-BBDE-4F19-83BF-1EBCFF19DA09 Q28551385-BA509F08-A694-4C47-9E4E-D28601F2F87F Q28575727-2016B033-7875-48ED-9D5F-DA3B4C09CDA9 Q28583542-B6F198C8-6BCA-4A39-A1F6-06E9B4F160DD Q28594677-ABD8D264-B9DC-4D65-8EBF-E9D41286DA84 Q30381503-F25DC716-D065-4E9C-AF4E-50B2870F937F Q30385717-2149113A-6F41-417A-B244-F2A9DE6AEDCD Q30417958-5CEE32DF-02CC-4E18-989F-ECA6886BD20D Q30494729-55EA1FBE-606A-48BF-80DB-7B5C2C80C420 Q30539041-0822A7DB-13B7-469C-9797-B3851DEA6172 Q30548444-6DC78999-9CC6-40FA-B3D7-9EC47FE157A1 Q30575578-FB920553-1811-4D4A-BB97-0A0533CB30FD

P2860

Chronic inhibition of cyclic GMP phosphodiesterase 5A prevents and reverses cardiac hypertrophy.

http://www.wikidata.org/entity/Q45235067

description

2005 nî lūn-bûn

@nan

2005年の論文

@ja

2005年学术文章

@wuu

2005年学术文章

@zh

2005年学术文章

@zh-cn

2005年学术文章

@zh-hans

2005年学术文章

@zh-my

2005年学术文章

@zh-sg

2005年學術文章

@yue

2005年學術文章

@zh-hant

name

Chronic inhibition of cyclic G ...... reverses cardiac hypertrophy.

@en

Chronic inhibition of cyclic G ...... reverses cardiac hypertrophy.

@nl

type

label

Chronic inhibition of cyclic G ...... reverses cardiac hypertrophy.

@en

Chronic inhibition of cyclic G ...... reverses cardiac hypertrophy.

@nl

prefLabel

Chronic inhibition of cyclic G ...... reverses cardiac hypertrophy.

@en

Chronic inhibition of cyclic G ...... reverses cardiac hypertrophy.

@nl

P1433

Q45235067-09074305-0637-4788-BB8B-F70D9F3BE100

P1476

Q45235067-733FDFEA-352D-4A42-99DE-F0D0B3B79C2F

P2093

Q45235067-1D584E11-0412-4D11-9EFE-9C50845F2154

Q45235067-24AE4A5C-7858-4DF9-BA21-A9DBDD2B1233

Q45235067-46BCF65D-67D2-4883-B327-4927880AC8A4

Q45235067-B1E02083-6806-4876-BF09-55C9C91C7C9C

Q45235067-C4D7FE6F-A926-4FF3-BCB8-C72C19F38B5D

Q45235067-C7594F7A-3F90-4176-96D3-5949A90DFF18

Q45235067-CCEDDF93-9835-414C-B71E-FC5B3C5A5CC4

Q45235067-D168FBEE-212D-4C2E-B77B-D28E5150ED41

Q45235067-DA1F8089-6357-40D0-A853-5020904DAD6E

P2860

Q45235067-13B35792-F748-4021-BDE8-FCB3ABBCFA51

Q45235067-1405F134-CD6F-44BA-9A9B-FBD612959D99

Q45235067-1E385B86-121E-4686-87AB-81A96EB75062

Q45235067-27A523E0-E091-4723-85B2-E9D86356F3A1

Q45235067-332A464E-6C0A-48A5-89A2-A546FADFA861

Q45235067-38F7D006-5E7A-428D-9854-08B6B37234B1

Q45235067-44814822-221D-430E-8061-8CC4E573BBA1

Q45235067-44955D38-0497-434B-B8EB-C1D49EB3BCE9

Q45235067-52144DA9-563E-4865-B3C2-2B7545FF6E46

Q45235067-588022DE-FFEF-42C4-B2B6-F58E3D991CBE

P2888

Q45235067-580E572C-C9E5-4C91-BC98-C66F97CF258F

P304

Q45235067-BA388682-13B9-4A04-AE08-9F94460A18A6

P31

Q45235067-E94D667E-A0F0-4932-8B5E-B5EC57C155DE

P356

Q45235067-019CA24E-314D-4568-A4B0-46B1E36786DC

P407

Q45235067-E63D8A30-E5A7-4CDF-8B87-5EBA8821B27E

P433

Q45235067-A0FCA62B-BA57-4DF2-B892-5DA795E70BC8

P478

Q45235067-9F6E36BC-5FF8-4E98-BC4A-3D865B14FF9C

P50

Q45235067-39DCE948-38C7-42D0-8F4A-516D5E4EA82A

P577

Q45235067-803C29F3-13B9-43A4-AB62-B7F9AD247751

P5875

Q45235067-9F55D051-696C-49E6-8165-489138E9851A

P6179

Q45235067-0A52F180-83BA-4139-A629-7B3A96D9620F

P698

Q45235067-91ED1177-2B57-4ED5-98B4-52DD46CAEE1B

P356

P1433

Nature Medicine

P1476

Chronic inhibition of cyclic G ...... reverses cardiac hypertrophy.

@en

P2093

David A Kass

http://www.w3.org/2001/XMLSchema#string

Diego Belardi

http://www.w3.org/2001/XMLSchema#string

Djahida Bedja

http://www.w3.org/2001/XMLSchema#string

E Rene Rodriguez

http://www.w3.org/2001/XMLSchema#string

Eiki Takimoto

http://www.w3.org/2001/XMLSchema#string

Hunter C Champion

http://www.w3.org/2001/XMLSchema#string

Kathleen L Gabrielson

http://www.w3.org/2001/XMLSchema#string

Manxiang Li

http://www.w3.org/2001/XMLSchema#string

Shuxun Ren

http://www.w3.org/2001/XMLSchema#string

P2860

Mitochondrial ATP-sensitive potassium channels inhibit apoptosis induced by oxidative stress in cardiac cells

A-kinase anchoring protein AKAP220 binds to glycogen synthase kinase-3beta (GSK-3beta ) and mediates protein kinase A-dependent inhibition of GSK-3beta

A calcineurin-dependent transcriptional pathway for cardiac hypertrophy

Pressure-independent enhancement of cardiac hypertrophy in natriuretic peptide receptor A-deficient mice

Calcineurin-mediated hypertrophy protects cardiomyocytes from apoptosis in vitro and in vivo: An apoptosis-independent model of dilated heart failure

Activated glycogen synthase-3 beta suppresses cardiac hypertrophy in vivo

Hypertension, cardiac hypertrophy, and sudden death in mice lacking natriuretic peptide receptor A

Increased activity of cGMP-specific phosphodiesterase (PDE5) contributes to resistance to atrial natriuretic peptide natriuresis in the pregnant rat

Impaired cardiac hypertrophic response in Calcineurin Abeta -deficient mice

PDE5 is converted to an activated state upon cGMP binding to the GAF A domain

P2888

P304

214-222

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/NM1175

http://www.w3.org/2001/XMLSchema#string

P407

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

11

http://www.w3.org/2001/XMLSchema#string

P50

P577

2005-01-23T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

8065494

http://www.w3.org/2001/XMLSchema#string

P6179

1045090677

http://www.w3.org/2001/XMLSchema#string

P698

15665834

http://www.w3.org/2001/XMLSchema#string